Biosensia is a biotechnology startup that specializes in Point-of-Care in-vitro diagnostics. The company offers the innovative RapiPlex platform, a rapid and practical diagnostics system compatible with various biological samples. Founded in 2000, Biosensia has received a notable €1.20M investment in a Venture Round on 19 December 2011, with backing from investors including Act Venture Capital, Atlantic Bridge Ventures, Enterprise Ireland, and Seroba Life Sciences.
RapiPlex, the company's flagship platform, integrates cutting-edge technologies to deliver a rapid, multiplexing Point-of-Care in-vitro diagnostics (IVD) system capable of supporting a wide array of diagnostic applications. The chip and cartridge system is designed to be compatible with various common biological sample types, including whole blood, serum, saliva, urine, and nasal/genital swabs. Biosensia operates within the biotechnology and healthcare industries, positioning itself as a pioneer in the development and licensing of advanced diagnostic solutions.
Overall, Biosensia's innovative approach to in-vitro diagnostics, supported by significant investment and prominent venture capital backing, positions the company for potential growth and impact within the healthcare and biotechnology sectors.
